C. D. Dinardo Et Al. , "AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A," CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.20, pp.179, 2020
Dinardo, C. D. Et Al. 2020. AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A. CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.20 , 179.
Dinardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., ... Döhner, H.(2020). AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A. CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.20, 179.
Dinardo, Courtney Et Al. "AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A," CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.20, 179, 2020
Dinardo, Courtney D. Et Al. "AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A." CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.20, pp.179, 2020
Dinardo, C. D. Et Al. (2020) . "AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A." CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.20, p.179.
@article{article, author={Courtney D. Dinardo Et Al. }, title={AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A}, journal={CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA}, year=2020, pages={179} }